Search results for "Ridge"

showing 10 items of 531 documents

Evolution of Pallial Areas and Networks Involved in Sociality: Comparison Between Mammals and Sauropsids

2019

Birds are extremely interesting animals for studying the neurobiological basis of cognition and its evolution. They include species that are highly social and show high cognitive capabilities. Moreover, birds rely more on visual and auditory cues than on olfaction for social behavior and cognition, just like primates. In primates, there are two major brain networks associated to sociality: (1) one related to perception and decision-making, involving the pallial amygdala (with the basolateral complex as a major component), the temporal and temporoparietal neocortex, and the orbitofrontal cortex; (2) another one related to affiliation, including the medial extended amygdala, the ventromedial …

0301 basic medicineArcopalliumPhysiologyOlfactionsocial cognitionBiologyNucleus accumbensAmygdalalcsh:PhysiologyDorsal ventricular ridge03 medical and health sciences0302 clinical medicineExtended amygdalaPhysiology (medical)Hypothesis and Theorymedicinemedial amygdalaaffiliationdorsal ventricular ridgeBSTMedial amygdalaNeocortexorbito frontal cortexAffiliationlcsh:QP1-981six part pallial modelpallial amygdalaSocial cognition030104 developmental biologymedicine.anatomical_structureNidopalliumOrbitofrontal cortexNeuroscience030217 neurology & neurosurgery
researchProduct

Gut Microbiota Condition the Therapeutic Efficacy of Trastuzumab in HER2-Positive Breast Cancer.

2021

Abstract Emerging evidence indicates that gut microbiota affect the response to anticancer therapies by modulating the host immune system. In this study, we investigated the impact of gut microbiota on immune-mediated trastuzumab antitumor efficacy in preclinical models of HER2-positive breast cancer and in 24 patients with primary HER2-positive breast cancer undergoing trastuzumab-containing neoadjuvant treatment. In mice, the antitumor activity of trastuzumab was impaired by antibiotic administration or fecal microbiota transplantation from antibiotic-treated donors. Modulation of the intestinal microbiota was reflected in tumors by impaired recruitment of CD4+ T cells and granzyme B–posi…

0301 basic medicineCD4-Positive T-LymphocytesCancer ResearchReceptor ErbB-2medicine.medical_treatmentGut floraGranzymesMice0302 clinical medicineAntineoplastic Agents ImmunologicalTrastuzumabTumor Microenvironmentskin and connective tissue diseasesNeoadjuvant therapybiologyFecal Microbiota TransplantationInterleukin-12Neoadjuvant TherapyAnti-Bacterial AgentsTreatment OutcomeOncology030220 oncology & carcinogenesisStreptomycinCytokinesGut microbiota trastuzumab breast cancerFemaleTaxoidsmedicine.drugBridged-Ring CompoundsBreast NeoplasmsSettore MED/08 - Anatomia PatologicaNitric Oxide03 medical and health sciencesImmune systemBreast cancerVancomycinmedicineAnimalsHumansCyclophosphamideImmunity Mucosalbusiness.industryLachnospiraceaeDendritic cellDendritic CellsTrastuzumabbiology.organism_classificationmedicine.diseaseGastrointestinal Microbiome030104 developmental biologyGranzymeDoxorubicinImmune Systembiology.proteinCancer researchInterferonsbusinessCancer research
researchProduct

Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasis.

2016

TP53 is a critical tumor suppressor gene that regulates cell cycle progression, apoptosis, cellular senescence and many other properties critical for control of normal cellular growth and death. Due to the pleiotropic effects that TP53 has on gene expression and cellular physiology, mutations at this tumor suppressor gene result in diverse physiological effects. T53 mutations are frequently detected in numerous cancers. The expression of TP53 can be induced by various agents used to treat cancer patients such as chemotherapeutic drugs and ionizing radiation. Radiation will induce Ataxia telangiectasia mutated (ATM) and other kinases that results in the phosphorylation and activation of TP53…

0301 basic medicineCancer Researchendocrine system diseasesMetastasimedicine.disease_causeMetastasisAntineoplastic AgentInvasionNeoplasmsTP53Neoplasm Metastasisbcl-2-Associated X ProteinAza CompoundProto-Oncogene ProteinApoptosis Regulatory ProteinbiologyCell CyclemiRMicroRNACell cycleCell biologyNeoplasm MetastasiGene Expression Regulation NeoplasticNutlin-3 chemosensitivityMdm2Molecular MedicineHumanSignal TransductionCyclin-Dependent Kinase Inhibitor p21Tumor suppressor genemiRsAntineoplastic AgentsCellular senescenceTP53; miRs; MDM2; Nutlin-3 chemosensitivity; Cellular senescence ; Invasion; Metastasis03 medical and health sciencesBcl-2-associated X proteinGeneticMDM2Proto-Oncogene ProteinsmicroRNAGeneticsmedicineHumansNeoplasm InvasivenessneoplasmsMolecular BiologyCell ProliferationNeoplasm InvasiveneAza CompoundsOncomirBridged Bicyclo Compounds HeterocyclicMicroRNAs030104 developmental biologyTumor progressionbiology.proteinNeoplasmTumor Suppressor Protein p53CarcinogenesisApoptosis Regulatory Proteins
researchProduct

Evaluation of the position of the posterior superior alveolar artery in relation to the maxillary sinus using the Cone-Beam computed tomography scans

2017

Background The aim of the present study was to evaluate the diameter, relationship and position of the posterior superior alveolar artery and its relationship with the alveolar ridge, the medial wall of the maxillary sinus, the prevalence of pathologic conditions and the maxillary sinus septa on CBCT images. Material and Methods A total of 200 CBCT images (400 maxillary sinuses) of patients over 20 years of age were evaluated. The distances between the lower border of the artery and the alveolar crest and between the artery and the medial wall of the sinus and the diameter of the artery were measured. The position of the artery, the presence of pathologic conditions and septa were recorded …

0301 basic medicineCone beam computed tomographyMaxillary sinusbusiness.industryResearchMaxillary artery030206 dentistryAnatomy:CIENCIAS MÉDICAS [UNESCO]Posterior superior alveolar artery03 medical and health sciences0302 clinical medicinemedicine.anatomical_structuremedicine.arteryUNESCO::CIENCIAS MÉDICASAlveolar ridgemedicinePeriodontology030101 anatomy & morphologyLateral wallbusinessGeneral DentistrySinus (anatomy)ArteryJournal of Clinical and Experimental Dentistry
researchProduct

Influence of supracrestal tissue attachment thickness on radiographic bone level around dental implants: A systematic review and meta-analysis.

2019

The present systematic review and meta-analysis was carried out to determine the extent to which supracrestal tissue attachment (STA) thickness affects marginal bone loss (MBL) around dental implants. An electronic search was conducted in PubMed (MEDLINE), EMBASE, and complementary sources covering the period up to June 2018. The studies were meta-analyzed based on implant position with respect to the alveolar bone crest (crestal/supracrestal). The MBL values were categorized according to STA width (thick/thin). Of the 1062 eligible titles, nine articles were included in the review. The implants were positioned crestal or supracrestal with respect to the alveolar ridge. The difference betwe…

0301 basic medicineDental Implantsbusiness.industryRadiographyDental Implantation EndosseousAlveolar Bone LossDentistrySoft tissue030206 dentistry03 medical and health sciences030104 developmental biology0302 clinical medicineDental Prosthesis DesignMeta-analysisStatistical significanceAlveolar ridgeAlveolar ProcessPeriodonticsMedicineHumansImplantBone levelbusinessDental alveolusJournal of periodontal researchREFERENCES
researchProduct

Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.

2020

Abstract Ibrutinib, obinutuzumab, and venetoclax demonstrate synergy in preclinical models of mantle cell lymphoma (MCL). OAsIs (NCT02558816), a single-arm multicenter prospective phase 1/2 trial, aimed to determine the maximum tolerated dose of venetoclax in combination with fixed doses of ibrutinib and obinutuzumab, in relapsed MCL patients. At the venetoclax MTD, extension cohorts were opened for relapsed and untreated patients. Safety and efficacy were secondary objectives. Minimal residual disease (MRD) was assessed by allele-specific oligonucleotide quantitative polymerase chain reaction. Between 14 October 2015 and 29 May 2018, 48 patients were enrolled. No dose-limiting toxicity was…

0301 basic medicineMaleNeoplasm Residualmedicine.medical_treatmentImmunoglobulin Variable RegionHematopoietic stem cell transplantationKaplan-Meier EstimateLymphoma Mantle-CellBiochemistryGastroenterologychemistry.chemical_compound0302 clinical medicinePiperidinesObinutuzumabAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesProspective cohort studyAged 80 and overSulfonamidesHematopoietic Stem Cell TransplantationHematologyMiddle AgedCombined Modality TherapyProgression-Free Survival3. Good healthTreatment Outcome030220 oncology & carcinogenesisIbrutinibFemaleImmunoglobulin Heavy Chainsmedicine.medical_specialtyMaximum Tolerated DoseImmunologyAntibodies Monoclonal Humanized03 medical and health sciencesInternal medicinemedicineHumansProgression-free survivalAgedVenetoclaxbusiness.industryAdenineCell Biologymedicine.diseaseBridged Bicyclo Compounds HeterocyclicGenes p53Minimal residual diseaseHematologic Diseases030104 developmental biologychemistryMutationMantle cell lymphomabusinessFollow-Up StudiesBlood
researchProduct

Distance of the alveolar antral artery from the alveolar crest. Related factors and surgical considerations in sinus floor elevation

2016

Background In a variable proportion of maxillary sinuses alveolar antral artery is located close to the residual ridge, increasing the chances for haemorrhagic complications during sinus floor elevation procedures. Material and Methods Retrospective observational study of CBCT explorations performed for implant-treatment planning. The upper first molar area was selected for this study. The relative uncertainty (standard deviation of the measurement divided by its mean and expressed as a percentage from 0% to 100%) was chosen for determining the observational errors. For modeling the chances of AAA detection, the generalized additive models (GAM) approach was chosen. Results A total of 240 m…

0301 basic medicineMaleSinus Floor AugmentationDentistrySinus Floor AugmentationSurgical planningMandibular first molar03 medical and health sciences0302 clinical medicinemedicineAlveolar ProcessMaxillaHumansGeneral DentistrySinus (anatomy)AgedRetrospective Studiesgeographygeography.geographical_feature_categorybusiness.industryResearch030206 dentistryArteriesMaxillary SinusMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.anatomical_structureOtorhinolaryngologyRidgeMaxillaUNESCO::CIENCIAS MÉDICASSurgeryCrest030101 anatomy & morphologyOral SurgerybusinessArtery
researchProduct

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomis…

2020

Background Venetoclax is a highly selective, potent, oral BCL-2 inhibitor, which induces apoptosis in multiple myeloma cells. Venetoclax plus bortezomib and dexamethasone has shown encouraging clinical efficacy with acceptable safety and tolerability in a phase 1 trial. The aim of this study was to evaluate venetoclax plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Methods In this randomised, double-blind, multicentre, phase 3 trial, patients aged 18 years or older with relapsed or refractory multiple myeloma, an Eastern Cooperative Oncology Group performance status of 2 or less, who had received one to three previous therapies were enrolled from …

0301 basic medicineMalemedicine.medical_specialtyTime FactorsPopulationNeutropeniaPlaceboDexamethasoneBortezomib03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodInternal medicineAntineoplastic Combined Chemotherapy ProtocolsClinical endpointMedicineHumansProgression-free survivaleducationAgededucation.field_of_studySulfonamidesbusiness.industryVenetoclaxBortezomibMiddle Agedmedicine.diseaseBridged Bicyclo Compounds HeterocyclicProgression-Free SurvivalVenetoclax BCL-2 inhibitor multiple myeloma Venetoclax plus bortezomib and dexamethasone030104 developmental biologyOncologychemistryTolerability030220 oncology & carcinogenesisFemalebusinessMultiple MyelomaProteasome Inhibitorsmedicine.drug
researchProduct

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study

2019

BackgroundEribulin mesylate (E) is indicated for metastatic breast cancer patients previously treated with anthracycline and taxane. We argued that E could also benefit patients eligible for neoadjuvant chemotherapy.MethodsPatients with primary triple negative breast cancer ≥2 cm received doxorubicin 60 mg/m2 and paclitaxel 200 mg/m2 x 4 cycles (AT) followed by E 1.4 mg/m2 x 4 cycles. Primary endpoint was pathological complete response (pCR) rate; secondary and explorative endpoints included clinical/metabolic response rates and safety, and biomarker analysis, respectively. Using a two-stage Simon design, 43 patients were to be included provided that 4 of 13 patients had achieved pCR in the…

0301 basic medicineOncologyCancer TreatmentTriple Negative Breast NeoplasmsImmunostainingToxicologyPathology and Laboratory MedicineBiochemistryMetastasis0302 clinical medicineBreast TumorsClinical endpointMedicine and Health Sciencesmetastatic breast cancer Eribulin mesylate epithelial–mesenchymal transition.AnthracyclinesTriple-negative breast cancerStainingMultidisciplinaryPharmaceuticsQRKetonesMetastatic breast cancerNeoadjuvant TherapyTreatment OutcomeSurgical OncologyOncology030220 oncology & carcinogenesisMedicineFemaleTaxoidsResearch ArticleAdultBridged-Ring CompoundsClinical Oncologymedicine.medical_specialtyAnthracyclineScienceSurgical and Invasive Medical ProceduresNeutropeniaResearch and Analysis Methods03 medical and health sciencesCancer ChemotherapyBreast cancerbreast cancerDrug TherapyInternal medicinemedicineHumansChemotherapyFuransTaxaneToxicitybusiness.industryCancers and NeoplasmsBiology and Life Sciencesmedicine.disease030104 developmental biologySpecimen Preparation and TreatmentMED/06 - ONCOLOGIA MEDICAClinical MedicinebusinessBiomarkers
researchProduct

Drugs and diseases: Summary and consensus statements of group 1. The 5th EAO Consensus Conference 2018

2018

OBJECTIVES: The task of this working group was to update the knowledge about the use of drugs and biologicals affecting healing of soft tissue and bone during implant treatment or procedures associated with it. Moreover, the impact of titanium particles and biocorrosion on complications and implant survival has been analysed. MATERIALS AND METHODS: The literature in the areas of interest (platelet concentrates, antiresorptive drugs as well as implant-host interaction) was screened using systematic reviews for the former two areas, whereas a narrative critical review was performed for the latter topic. Two manuscripts on platelet concentrates, one manuscript on antiresorptive drugs and one m…

0301 basic medicineTechnologymedicine.medical_specialtymedication-related osteonecrosis of the jawsplatelet-rich fibrin610 Medicine & healthOdontologi03 medical and health sciencesEngineering0302 clinical medicinesystematic reviewguided bone regeneration sinus floor elevationdental implantsDentistry Oral Surgery & Medicinemedicineantiresorptive drugstitanium610 Medicine & healthEngineering BiomedicalbisphosphonatesScience & Technologycorrosionbusiness.industryConsensus conferenceimplant therapyplatelet-rich plasma030206 dentistryddc:617.63. Good healthhormone replacement therapyAntiresorptive Drugs030104 developmental biologySystematic reviewGroup analysisDentistryFamily medicinealveolar ridge preservationOral SurgerybusinessLife Sciences & Biomedicineperi-implantitisClinical Oral Implants Research
researchProduct